clonidine has been researched along with Abstinence Syndrome, Neonatal in 32 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study goal was to determine whether clonidine treatment of neonatal abstinence syndrome (NAS) would result in a better neurobehavioral performance compared with morphine." | 9.20 | Morphine versus clonidine for neonatal abstinence syndrome. ( Bada, HS; Breheny, P; Caldwell, R; Capilouto, G; Garlitz, K; Gibson, J; Leggas, M; Li, Y; Sithisarn, T, 2015) |
| "To compare the efficacy of clonidine versus phenobarbital in reducing morphine sulfate treatment days for neonatal abstinence syndrome (NAS)." | 9.17 | Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. ( Chamberlain, S; Kopcza, K; Shah, B; Singh, R; Surran, B; Visintainer, P, 2013) |
| "The population pharmacokinetic (PK) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome, and significant covariates affecting its PK parameters were identified." | 9.15 | Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. ( Agthe, AG; Cao, YJ; Gauda, EB; Hendrix, CW; Lee, H; Xie, HG, 2011) |
| "To determine if oral clonidine would reduce the duration of opioid detoxification for neonatal abstinence syndrome." | 9.14 | Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. ( Agthe, AG; Chavez-Valdez, R; Gauda, EB; Hendrix, CW; Jansson, L; Kim, GR; Lewis, TR; Mathias, KB; Yaster, M, 2009) |
| "To provide a systematic review of the current role of clonidine in neonatal abstinence syndrome (NAS)." | 8.93 | Role of Clonidine in Neonatal Abstinence Syndrome: A Systematic Review. ( Gildon, BL; Streetz, VN; Thompson, DF, 2016) |
| "To undertake a literature search and critical appraisal of best available evidence to answer the clinical question: Does the addition of clonidine (I) to standard treatment with an opioid (C) improve outcomes (O) in infants with Neonatal Abstinence Syndrome? A search of both comprehensive (MedLine and Embase) and pre-filtered databases (Dynamed, UpToDate and TRIP), utilising Boolean Operators to combine search terms appropriately." | 8.02 | Does the addition of clonidine to opioid therapy improve outcomes in infants with Neonatal Abstinence Syndrome? ( D'Abaco, E, 2021) |
| "To compare clonidine versus phenobarbital as adjunctive therapy in infants who failed monotherapy with morphine for neonatal abstinence syndrome (NAS)." | 7.96 | Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. ( Brusseau, C; Burnette, T; Heidel, RE, 2020) |
| "To examine whether adding clonidine to the morphine regimen for treatment of neonatal abstinence syndrome (NAS) is associated with a shorter length of treatment compared with morphine alone." | 7.91 | Comparison of outcomes between morphine and concomitant morphine and clonidine treatments for neonatal abstinence syndrome. ( Campbell-Yeo, M; Gullickson, C; Kuhle, S, 2019) |
| "Extemporaneously prepared clonidine admixture is increasingly used for the management of neonatal abstinence syndrome." | 7.91 | Physicochemical stability of extemporaneously prepared clonidine solutions for use in neonatal abstinence syndrome. ( Harmanjeet, H; Lu, D; Paine, M; Patel, RP; Peterson, GM; Wanandy, T, 2019) |
| "This study suggests that a treatment of neonatal abstinence syndrome with clonidine in omission of opiates is possible without causing short-term adverse cardiovascular effects." | 7.76 | Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate. ( Bastanier, C; Beske, F; Esmaeili, A; Keinhorst, AK; Schlösser, R; Schuster, T, 2010) |
| "The study goal was to determine whether clonidine treatment of neonatal abstinence syndrome (NAS) would result in a better neurobehavioral performance compared with morphine." | 5.20 | Morphine versus clonidine for neonatal abstinence syndrome. ( Bada, HS; Breheny, P; Caldwell, R; Capilouto, G; Garlitz, K; Gibson, J; Leggas, M; Li, Y; Sithisarn, T, 2015) |
| "To compare the efficacy of clonidine versus phenobarbital in reducing morphine sulfate treatment days for neonatal abstinence syndrome (NAS)." | 5.17 | Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. ( Chamberlain, S; Kopcza, K; Shah, B; Singh, R; Surran, B; Visintainer, P, 2013) |
| "The population pharmacokinetic (PK) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome, and significant covariates affecting its PK parameters were identified." | 5.15 | Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. ( Agthe, AG; Cao, YJ; Gauda, EB; Hendrix, CW; Lee, H; Xie, HG, 2011) |
| "To determine if oral clonidine would reduce the duration of opioid detoxification for neonatal abstinence syndrome." | 5.14 | Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. ( Agthe, AG; Chavez-Valdez, R; Gauda, EB; Hendrix, CW; Jansson, L; Kim, GR; Lewis, TR; Mathias, KB; Yaster, M, 2009) |
| "To provide a systematic review of the current role of clonidine in neonatal abstinence syndrome (NAS)." | 4.93 | Role of Clonidine in Neonatal Abstinence Syndrome: A Systematic Review. ( Gildon, BL; Streetz, VN; Thompson, DF, 2016) |
| "To undertake a literature search and critical appraisal of best available evidence to answer the clinical question: Does the addition of clonidine (I) to standard treatment with an opioid (C) improve outcomes (O) in infants with Neonatal Abstinence Syndrome? A search of both comprehensive (MedLine and Embase) and pre-filtered databases (Dynamed, UpToDate and TRIP), utilising Boolean Operators to combine search terms appropriately." | 4.02 | Does the addition of clonidine to opioid therapy improve outcomes in infants with Neonatal Abstinence Syndrome? ( D'Abaco, E, 2021) |
| "To compare clonidine versus phenobarbital as adjunctive therapy in infants who failed monotherapy with morphine for neonatal abstinence syndrome (NAS)." | 3.96 | Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. ( Brusseau, C; Burnette, T; Heidel, RE, 2020) |
| "To examine whether adding clonidine to the morphine regimen for treatment of neonatal abstinence syndrome (NAS) is associated with a shorter length of treatment compared with morphine alone." | 3.91 | Comparison of outcomes between morphine and concomitant morphine and clonidine treatments for neonatal abstinence syndrome. ( Campbell-Yeo, M; Gullickson, C; Kuhle, S, 2019) |
| " We present a case report of a neonate born to a 25-year-old mother enrolled in a medication-assisted treatment program for substance use disorder who was noncompliant in prenatal care, using multiple substances throughout the pregnancy, including gabapentin and fentanyl." | 3.91 | Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog. ( Davies, TH; Hansen, Z; Loudin, S; Murray, S; Nellhaus, EM, 2019) |
| "A high-performance liquid chromatography-tandem mass spectrometry method was developed and validated for the simultaneous quantification of morphine, morphine's major metabolites morphine-3-glucuronide and morphine-6-glucuronide, and clonidine, to support the pharmacokinetic analysis of an ongoing double-blinded randomized clinical trial that compares the use of morphine and clonidine in infants diagnosed with neonatal abstinence syndrome." | 3.91 | Validation of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its metabolites in human plasma. ( Bada, H; Leggas, M; Ng, CM; Tang, F, 2019) |
| "Extemporaneously prepared clonidine admixture is increasingly used for the management of neonatal abstinence syndrome." | 3.91 | Physicochemical stability of extemporaneously prepared clonidine solutions for use in neonatal abstinence syndrome. ( Harmanjeet, H; Lu, D; Paine, M; Patel, RP; Peterson, GM; Wanandy, T, 2019) |
| "This study suggests that a treatment of neonatal abstinence syndrome with clonidine in omission of opiates is possible without causing short-term adverse cardiovascular effects." | 3.76 | Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate. ( Bastanier, C; Beske, F; Esmaeili, A; Keinhorst, AK; Schlösser, R; Schuster, T, 2010) |
| "When opioid misuse rises in the United States, pregnant women and their neonates are affected." | 2.61 | Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. ( Jones, HE; Kraft, WK, 2019) |
| "Clonidine was a significantly better adjunctive therapy than phenobarbital in reducing morphine treatment days." | 2.61 | Therapeutic approaches for neonatal abstinence syndrome: a systematic review of randomized clinical trials. ( Ghazanfarpour, M; Keramat-Roudi, A; Mashhadi, ME; Mégarbane, B; Moghaddam, MMM; Najafi, MN; Rezaee, R; Roozbeh, N; Tsatsakis, A, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 4 (12.50) | 29.6817 |
| 2010's | 19 (59.38) | 24.3611 |
| 2020's | 7 (21.88) | 2.80 |
| Authors | Studies |
|---|---|
| Clemans-Cope, L | 1 |
| Holla, N | 1 |
| Lee, HC | 1 |
| Cong, AS | 1 |
| Castro, R | 1 |
| Chyi, L | 1 |
| Huang, A | 1 |
| Taylor, KJ | 1 |
| Kenney, GM | 1 |
| Brusseau, C | 1 |
| Burnette, T | 1 |
| Heidel, RE | 1 |
| Stephanie, A | 1 |
| Caldwell, CD | 1 |
| Fraser, D | 1 |
| Joseph, R | 1 |
| Goodall, HD | 1 |
| Ridky, J | 1 |
| Rudd, K | 1 |
| Williams, L | 1 |
| D'Abaco, E | 1 |
| Merhar, SL | 1 |
| Ounpraseuth, S | 1 |
| Devlin, LA | 1 |
| Poindexter, BB | 1 |
| Young, LW | 1 |
| Berkey, SD | 1 |
| Crowley, M | 1 |
| Czynski, AJ | 1 |
| Kiefer, AS | 1 |
| Whalen, BL | 1 |
| Das, A | 1 |
| Fuller, JF | 1 |
| Higgins, RD | 1 |
| Thombre, V | 1 |
| Lester, BM | 1 |
| Smith, PB | 1 |
| Newman, S | 1 |
| Sánchez, PJ | 1 |
| Smith, MC | 1 |
| Simon, AE | 1 |
| Zankl, A | 2 |
| Martin, J | 2 |
| Davey, JG | 2 |
| Osborn, DA | 5 |
| Wachman, EM | 2 |
| Schiff, DM | 1 |
| Silverstein, M | 1 |
| Gullickson, C | 1 |
| Kuhle, S | 1 |
| Campbell-Yeo, M | 1 |
| Nellhaus, EM | 1 |
| Murray, S | 1 |
| Hansen, Z | 1 |
| Loudin, S | 1 |
| Davies, TH | 1 |
| Tang, F | 1 |
| Bada, H | 1 |
| Ng, CM | 1 |
| Leggas, M | 2 |
| Jones, HE | 1 |
| Kraft, WK | 1 |
| Ghazanfarpour, M | 1 |
| Najafi, MN | 1 |
| Roozbeh, N | 1 |
| Mashhadi, ME | 1 |
| Keramat-Roudi, A | 1 |
| Mégarbane, B | 1 |
| Tsatsakis, A | 1 |
| Moghaddam, MMM | 1 |
| Rezaee, R | 1 |
| Lu, D | 1 |
| Harmanjeet, H | 1 |
| Wanandy, T | 1 |
| Paine, M | 1 |
| Peterson, GM | 1 |
| Patel, RP | 1 |
| Parikh, A | 1 |
| Gopalakrishnan, M | 1 |
| Azeem, A | 1 |
| Booth, A | 1 |
| El-Metwally, D | 1 |
| Surran, B | 1 |
| Visintainer, P | 1 |
| Chamberlain, S | 1 |
| Kopcza, K | 1 |
| Shah, B | 1 |
| Singh, R | 2 |
| Coyle, MG | 1 |
| Visintainer, PF | 1 |
| Bagley, SM | 1 |
| Holland, E | 1 |
| Brogly, SB | 1 |
| Bada, HS | 1 |
| Sithisarn, T | 1 |
| Gibson, J | 1 |
| Garlitz, K | 1 |
| Caldwell, R | 1 |
| Capilouto, G | 1 |
| Li, Y | 1 |
| Breheny, P | 1 |
| Streetz, VN | 1 |
| Gildon, BL | 1 |
| Thompson, DF | 1 |
| McPherson, C | 1 |
| Agthe, AG | 2 |
| Kim, GR | 1 |
| Mathias, KB | 1 |
| Hendrix, CW | 2 |
| Chavez-Valdez, R | 1 |
| Jansson, L | 1 |
| Lewis, TR | 1 |
| Yaster, M | 1 |
| Gauda, EB | 2 |
| Leikin, JB | 1 |
| Mackendrick, WP | 1 |
| Maloney, GE | 1 |
| Rhee, JW | 1 |
| Farrell, E | 1 |
| Wahl, M | 1 |
| Kelly, K | 1 |
| Esmaeili, A | 1 |
| Keinhorst, AK | 1 |
| Schuster, T | 1 |
| Beske, F | 1 |
| Schlösser, R | 1 |
| Bastanier, C | 1 |
| Xie, HG | 1 |
| Cao, YJ | 1 |
| Lee, H | 1 |
| Jeffery, HE | 3 |
| Cole, MJ | 3 |
| Bio, LL | 1 |
| Siu, A | 1 |
| Poon, CY | 1 |
| Little, PJ | 1 |
| Price, RR | 1 |
| Hinton, RK | 1 |
| Kuhn, CM | 1 |
| Theis, JG | 1 |
| Selby, P | 1 |
| Ikizler, Y | 1 |
| Koren, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome[NCT02851303] | Phase 4 | 61 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Pharmacological Treatment of Neonatal Abstinence Syndrome: Opiate Versus Non-Opiate[NCT01734551] | Phase 4 | 31 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy[NCT03092011] | Phase 4 | 90 participants (Anticipated) | Interventional | 2018-02-21 | Recruiting | ||
| Treatment of Neonatal Abstinence Syndrome: Evaluation of Efficacy of Phenobarbital in Combination With Either Methadone or Diluted Deodorized Tincture of Opium as Stabilizing and Tapering Regiments[NCT01723722] | Phase 4 | 40 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Improving Outcomes in Neonatal Abstinence Syndrome[NCT01958476] | Phase 3 | 117 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome[NCT01452789] | Phase 3 | 63 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS)[NCT01708707] | Phase 2 | 29 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Comparison of Clonidine Versus Phenobarbital as an Adjunct Therapy for Neonatal Abstinence Syndrome[NCT01175668] | 68 participants (Actual) | Interventional | 2010-07-31 | Terminated (stopped due to Based on the planned interim analysis results at 50% recruitment, after IRB reviewed the results, further enrollment was stopped.) | |||
| Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain[NCT03396588] | Phase 3 | 120 participants (Actual) | Interventional | 2017-12-07 | Active, not recruiting | ||
| Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial[NCT00510016] | Phase 2 | 80 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Phase I-II Clinical Trial to Determine the Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia[NCT01862250] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2013-10-03 | Completed | ||
| Efficacy of Clonidine in Reducing Iatrogenic-induced Opioid Dependence in Infants:[NCT01360450] | Phase 2/Phase 3 | 12 participants (Actual) | Interventional | 2011-07-31 | Terminated (stopped due to The study was treminated because of low accural) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assessed through chart review of discharge summary documentation of method of infant feeding at time of discharge (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 5 |
| Methadone | 5 |
Number of days in hospital after birth (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | days (Mean) |
|---|---|
| Morphine | 17.9 |
| Methadone | 16.1 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | days (Mean) |
|---|---|
| Morphine | 14.7 |
| Methadone | 12.8 |
clonidine (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 1 |
| Methadone | 0 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 11 |
| Methadone | 6 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Morphine | 0 |
| Methadone | 3 |
(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days
| Intervention | morphine equivalents mg (Mean) |
|---|---|
| Morphine | 9.86 |
| Methadone | 33.0 |
Total number days of treatment (NCT01734551)
Timeframe: 120 days
| Intervention | days (Median) |
|---|---|
| Morphine | 39 |
| Clonidine | 27 |
Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15. Scores below 1 standard deviation (= or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain The score for each domain (motor, cognitive, and language functioning) represents the full-scale score (NCT01734551)
Timeframe: 1 year of life
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Bayley III motor | Cognitive | Language total | Language Receptive | Language Expressive | |
| Clonidine | 95.8 | 93.3 | 95.8 | 95.0 | 99.2 |
| Morphine | 97.6 | 92.9 | 98.0 | 101.1 | 100.0 |
Mean of total Finnegan Scores obtained every 3 hours on days 2, 7, and 14 following start of treatment; A score is a number representing the total score or sum from 21 items or symptoms or manifestations of opiate withdrawal in newborn infants. The total score ranges from 0 to 43. Reference: 1. Finnegan LP, Connaughton JF, Jr., Kron RE, et al. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2(1-2):141-58. Although normal newborn may manifest mild symptoms that will give scores in the range of 0 to 7. A score of 8 consecutively obtained times 3 indicate that infant will benefit from treatment, in this study morphine or clonidine. A decrease in scores especially to less than 8 is suggestive of a good response to treatment. (NCT01734551)
Timeframe: 14 days
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Finnegan scores day 2 of treatment | Finnegan scores day 7 of treatment | Finnegan scores day 14 of treatment | |
| Clonidine | 8.5 | 5.7 | 6.7 |
| Morphine | 7.5 | 6.6 | 7.1 |
The summary scores from the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) give a measure of infant neurobehavior in the following areas (score range): habituation (1-9), regulation (2.20-7.50), attention (1.29 -8.4), Handling (0 - 1), quality of movement (1.20 - 6.20), Non-optimal reflexes (0-12), Asymmetric reflexes (0-7), arousal (2.43 - 6.67), hypertonicity (0- 8), hypotonicity (0 - 5.0), excitability (0-11), lethargy (0 - 11.0). and stress/abstinence (0. - 0.57). A higher score for each item means a higher level of the construct. For example, a higher score for hypertonicity means the infant is more hypertonic and higher score on hypotonicity means the infant is more hypotonic. No cut-off score published for normal or abnormal behavioral performance. Reference: Lester BM et al. Summary Statistics of Neonatal Intensive Care Unit Network Neurobehavioral Scale Scores From the Maternal Lifestyle Study: A Quasinormative Sample, in Pediatrics 2004; 113,668. (NCT01734551)
Timeframe: 5-10 days after treatment starts
| Intervention | scores on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Attention | Handling | Quality of movement | Regulation | Non-optimal reflexes | Asymmetric reflexes | Stress/abstinence | Arousal | Hypertonicity | Hypotonicity | Excitability | Lethargy | |
| Clonidine | 4.51 | 0.42 | 4.92 | 5.26 | 4.13 | 0.00 | 0.08 | 3.95 | 0.25 | 0.19 | 2.38 | 5.13 |
| Morphine | 5.06 | 0.36 | 4.77 | 5.2 | 3.73 | 0.20 | 0.07 | 3.91 | 0.40 | 0.13 | 2.6 | 3.6 |
Up to 12 months (NCT01723722)
Timeframe: Up to 12 months
| Intervention | days (Mean) |
|---|---|
| Deodorized Tincture Opium After Phenobarbital for Withdrawal | 19.1 |
| Methadone After Phenobarbital for Withdrawal | 17.7 |
Average head circumference growth outcome at 18 month follow-up visit. (NCT01958476)
Timeframe: 18 month follow-up visit
| Intervention | cm (Mean) |
|---|---|
| Methadone | 47.8 |
| Neonatal Morphine Solution | 48.2 |
Average length (cm) at 18 month follow-up visit. (NCT01958476)
Timeframe: 18 month follow-up visit
| Intervention | cm (Mean) |
|---|---|
| Methadone | 82.1 |
| Neonatal Morphine Solution | 81.7 |
Growth outcome weight (lbs) depicted as difference in averaged weights from birth to 18 month follow-up visit. Standard deviations were averaged between birth and 18 mo time points. (NCT01958476)
Timeframe: Birth to 18 month follow-up visit
| Intervention | lbs (Mean) |
|---|---|
| Methadone | 19.1 |
| Neonatal Morphine Solution | 18.7 |
Participants were monitored for the duration of their hospitalization, an expected mean of 22 days. (NCT01958476)
Timeframe: Participants will be monitored during their entire hospitalization, expected mean 22 days.
| Intervention | days (Mean) |
|---|---|
| Methadone | 21.8 |
| Neonatal Morphine Solution | 23.2 |
Participants were monitored for the duration of their hospitalization attributable to NAS only. (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, expected mean 22 days.
| Intervention | days (Mean) |
|---|---|
| Methadone | 18.9 |
| Neonatal Morphine Solution | 21.1 |
Total number of days infant treated with replacement opioids while admitted to the hospital. (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization.
| Intervention | days (Mean) |
|---|---|
| Methadone | 14.7 |
| Neonatal Morphine Solution | 16.6 |
"One Finnegan score ≥12, or two consecutive scores ≥8 affirms the requirement for pharmacological treatment or increasing treatment dosage. If the infant continued to have two consecutive Finnegan Scores ≥8 two times consecutively, or one ≥12, the dose was increased to the next level. (Level I: 0.3 mg/kg/day) (Level II: 0.5 mg/kg/day) (Level III: 0.7 mg/kg/day)~A higher Finnegan score indicates greater severity of NAS (min 0, max 50)." (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, an average of 22 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Methadone | 22 |
| Neonatal Morphine Solution | 28 |
Number of infants treated with a second medication following protocol, phenobarbital. If the Finnegan Score remained elevated (still scored ≥8 two times consecutively, or still scored once ≥12) despite increasing to a predetermined maximal opioid dose (methadone or morphine), phenobarbital was administered (20-mg/kg loading dose followed by 4-5 mg/kg daily). (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, an average of 22 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Methadone | 10 |
| Neonatal Morphine Solution | 17 |
The Bayley Scales of Infant and Toddler Development (BSID-III) assesses the development of infants and children (1-42 months) through a series of developmental play tasks, identifying children with developmental delay. Raw scores of completed items are summarized within three distinct scale scores (Cognitive Scale, Language Scale, Motor Scale). Scale scores are each converted to composite scores to determine the child's performance compared with scores of age-matched children of typical development (percentile rank). A higher composite score indicates more ideal developmental outcome (range 40-160). At 18 month follow-up visit, participants were assessed using the BSID-III for cognitive, language and motor scale composite score outcomes. (NCT01958476)
Timeframe: Assessment at 18 month follow-up visit
| Intervention | scores on a scale (Composite) (Mean) | ||
|---|---|---|---|
| Cognitive Composite | Language Composite | Motor Composite | |
| Methadone | 100.1 | 96.0 | 103.6 |
| Neonatal Morphine Solution | 98.1 | 94.2 | 99.1 |
This endpoint will compare length of stay in the hospital (in days) using sublingual buprenorphine or morphine solution. (NCT01452789)
Timeframe: Duration of hospital stay is an expected average of 5 weeks.
| Intervention | days (Median) |
|---|---|
| Sublingual Buprenorphine | 21 |
| Oral Morphine | 33 |
This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | days (Median) |
|---|---|
| Sublingual Buprenorphine | 15 |
| Oral Morphine | 28 |
Adverse events will be collected, graded by severity, and assessed for causality referent to study drug. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sublingual Buprenorphine | 7 |
| Oral Morphine | 8 |
This endpoint will compare requirement number of patients who require use of supplemental phenobarbital. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.
| Intervention | participants (Number) |
|---|---|
| Sublingual Buprenorphine | 5 |
| Oral Morphine | 7 |
(NCT01175668)
Timeframe: subjects were followed for the duration of treatment, up to 3 months
| Intervention | days (Mean) |
|---|---|
| NMS/Clonidine | 18.2 |
| NMS/Phenobarbital | 13.6 |
(NCT01175668)
Timeframe: For the duration of treatment, upto 3 months
| Intervention | mg/kg (Mean) |
|---|---|
| NMS/Clonidine | 5.7 |
| NMS/Phenobarbital | 4.6 |
Intravenous morphine (mg/kg) was given. The standard dose is 0.05 mg/kg per dose (NCT01862250)
Timeframe: Up to 2 days
| Intervention | mg/kg (Median) |
|---|---|
| Clonidine Infants With HIE | 0.02 |
Babies were assessed after administration of clonidine for the presence or absence of shivering. (NCT01862250)
Timeframe: 48hrs
| Intervention | Participants (Count of Participants) |
|---|---|
| Clonidine Infants With HIE | 0 |
"Trough clonidine blood levels were measured after 4-7 doses of clonidine were given intravenously with a dosing interval of every 8 hrs. Mean and standard deviation (SD) of the number of doses given prior to levels being drawn was 5.3 (mean) and 0.37 (SD).~Time after last dose before measurement was 9hrs (mean) and 2.7hrs (SD)." (NCT01862250)
Timeframe: 3 days
| Intervention | ng/ml (Median) |
|---|---|
| Clonidine Infants With HIE | 0.6 |
Following 2 hours of therapeutic hypothermia, the temperature of the thermo-blanket is adjusted up half degree per hour allowing passive rewarming until 36.5 degrees is reached (NCT01862250)
Timeframe: Beginning at 72 hours up to 12 hours
| Intervention | Hours (Median) |
|---|---|
| Clonidine Infants With HIE | 8.7 |
Time to complete detoxification is defined as 48 hrs off all opioids/benzodiazepines and study drug with acceptable withdrawal scores of <9 (on average we expect the infant to be enrolled in the study for 2-4 weeks). The scale used to assess withdrawal was the Modified Finnegan Neonatal Withdrawal Scale, which ranges from 0-41, 0 represents no withdrawal and 41 represent maximum withdrawal. (NCT01360450)
Timeframe: up to 4 weeks
| Intervention | days (Mean) | |
|---|---|---|
| total days on narcotics | duration on study drug in days | |
| Control | 37.2 | 14.2 |
| Treatment | 89.5 | 21 |
13 reviews available for clonidine and Abstinence Syndrome, Neonatal
| Article | Year |
|---|---|
Sedatives for opioid withdrawal in newborn infants.
Topics: Bias; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Narcoti | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Opioid treatment for opioid withdrawal in newborn infants.
Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn | 2021 |
Neonatal Abstinence Syndrome: Advances in Diagnosis and Treatment.
Topics: Acupuncture Therapy; Analgesics; Breast Feeding; Buprenorphine; Clonidine; Female; Humans; Infant, N | 2018 |
Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome.
Topics: Analgesia, Obstetrical; Analgesics; Analgesics, Opioid; Breast Feeding; Buprenorphine; Buprenorphine | 2019 |
Therapeutic approaches for neonatal abstinence syndrome: a systematic review of randomized clinical trials.
Topics: Analgesics, Opioid; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Infant, Newborn; Le | 2019 |
Review of the assessment and management of neonatal abstinence syndrome.
Topics: Breast Feeding; Buprenorphine; Clonidine; Female; Humans; Infant, Newborn; Methadone; Narcotics; Neo | 2014 |
Role of Clonidine in Neonatal Abstinence Syndrome: A Systematic Review.
Topics: Analgesics, Opioid; Clonidine; Humans; Infant, Newborn; Neonatal Abstinence Syndrome | 2016 |
Pharmacotherapy for Neonatal Abstinence Syndrome: Choosing the Right Opioid or No Opioid at All.
Topics: Analgesics; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Hypnotics and Sedatives; In | 2016 |
Sedatives for opiate withdrawal in newborn infants.
Topics: Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Narcotics; Ne | 2010 |
Update on the pharmacologic management of neonatal abstinence syndrome.
Topics: Benzodiazepines; Buprenorphine; Clonidine; Female; Humans; Hypnotics and Sedatives; Infant, Newborn; | 2011 |
Sedatives for opiate withdrawal in newborn infants.
Topics: Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Neonatal Abst | 2002 |
Sedatives for opiate withdrawal in newborn infants.
Topics: Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Neonatal Abst | 2005 |
Current management of the neonatal abstinence syndrome: a critical analysis of the evidence.
Topics: Analgesics, Opioid; Anticonvulsants; Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; | 1997 |
4 trials available for clonidine and Abstinence Syndrome, Neonatal
| Article | Year |
|---|---|
Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Analysis of Variance; Clonidine; Drug Ther | 2013 |
Morphine versus clonidine for neonatal abstinence syndrome.
Topics: Analgesics; Arousal; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2015 |
Morphine versus clonidine for neonatal abstinence syndrome.
Topics: Analgesics; Arousal; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2015 |
Morphine versus clonidine for neonatal abstinence syndrome.
Topics: Analgesics; Arousal; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2015 |
Morphine versus clonidine for neonatal abstinence syndrome.
Topics: Analgesics; Arousal; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 2015 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination; | 2009 |
Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome.
Topics: Administration, Oral; Adrenergic alpha-2 Receptor Agonists; Clonidine; Double-Blind Method; Humans; | 2011 |
15 other studies available for clonidine and Abstinence Syndrome, Neonatal
| Article | Year |
|---|---|
Neonatal abstinence syndrome management in California birth hospitals: results of a statewide survey.
Topics: Analgesics, Opioid; Breast Feeding; California; Clonidine; Health Care Surveys; Humans; Infant Care; | 2020 |
Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome.
Topics: Analgesics, Opioid; Clonidine; Humans; Infant, Newborn; Length of Stay; Methadone; Morphine; Neonata | 2020 |
Academy News.
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Catheter-Related Infections; Clinical Competence; Cloni | 2020 |
Does the addition of clonidine to opioid therapy improve outcomes in infants with Neonatal Abstinence Syndrome?
Topics: Analgesics, Opioid; Clonidine; Drug Therapy, Combination; Humans; Infant; Infant, Newborn; Neonatal | 2021 |
Phenobarbital and Clonidine as Secondary Medications for Neonatal Opioid Withdrawal Syndrome.
Topics: Analgesics; Analgesics, Opioid; Clonidine; Drug Administration Schedule; Drug Therapy, Combination; | 2021 |
Comparison of outcomes between morphine and concomitant morphine and clonidine treatments for neonatal abstinence syndrome.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Clonidine; Drug Therapy, Combination; Fema | 2019 |
Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog.
Topics: Anticonvulsants; Clonidine; Female; Fentanyl; Humans; Infant, Newborn; Levetiracetam; Methadone; Myo | 2019 |
Validation of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its metabolites in human plasma.
Topics: Chromatography, High Pressure Liquid; Clonidine; Drug Stability; Humans; Infant, Newborn; Limit of D | 2019 |
Physicochemical stability of extemporaneously prepared clonidine solutions for use in neonatal abstinence syndrome.
Topics: Clonidine; Drug Packaging; Drug Stability; Drug Storage; Glass; Humans; Infant, Newborn; Neonatal Ab | 2019 |
Racial association and pharmacotherapy in neonatal opioid withdrawal syndrome.
Topics: Analgesics; Black or African American; Clonidine; Drug Therapy, Combination; Female; Humans; Infant, | 2019 |
Adjunctive therapy for neonatal opioid dependence: do we really know what's best?
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Clonidine; Female; Humans; Male; Morphine; | 2014 |
Adjunctive therapy for neonatal abstinence syndrome: why not personalize it for each infant based on their in-utero exposure?
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Clonidine; Female; Humans; Male; Morphine; | 2014 |
Use of clonidine in the prevention and management of neonatal abstinence syndrome.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Clonidine; Drug Therapy, Combination; Female; Gesta | 2009 |
Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate.
Topics: Blood Pressure; Chloral Hydrate; Clonidine; Drug Therapy, Combination; Female; Humans; Hypnotics and | 2010 |
Role of noradrenergic hyperactivity in neonatal opiate abstinence.
Topics: Adrenergic alpha-Agonists; Animals; Animals, Newborn; Brain; Clonidine; Humans; Infant, Newborn; Met | 1996 |